<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02490800</url>
  </required_header>
  <id_info>
    <org_study_id>CDI-CS-002</org_study_id>
    <nct_id>NCT02490800</nct_id>
  </id_info>
  <brief_title>Phase 1/2a Study of Oral BAL101553 in Adult Patients With Solid Tumors or Glioblastoma or High-grade Glioma</brief_title>
  <official_title>An Open-label Phase 1/2a Study of Oral BAL101553 in Adult Patients With Advanced Solid Tumors and in Adult Patients With Recurrent or Progressive Glioblastoma or High-grade Glioma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Basilea Pharmaceutica</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Basilea Pharmaceutica</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      First in human, open-label, sequential dose escalation and expansion study of oral BAL101553&#xD;
      in adult patients with advanced solid tumors and adult patients with recurrent or progressive&#xD;
      glioblastoma or high-grade glioma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is the first study of the oral formulation of BAL101553. BAL101553 will be administered&#xD;
      once daily during each day of a 28-day treatment cycle in capsule form to adults with&#xD;
      advanced or recurrent solid tumors or recurrent or progressive glioblastoma or high-grade&#xD;
      glioma who have failed standard therapy, or for whom no effective standard therapy is&#xD;
      available.&#xD;
&#xD;
      In Phase 1, the highest dose of BAL101553 was determined that can safely be given to adults&#xD;
      with advanced or recurrent solid tumors, recurrent or progressive glioblastoma or high-grade&#xD;
      glioma who have failed standard therapy, or for whom no effective standard therapy is&#xD;
      available.&#xD;
&#xD;
      In Phase 2a, the tolerability and potential anticancer activity of oral BAL101553 will be&#xD;
      assessed in patients with recurrent glioblastoma whose tumor tissue tests positive for&#xD;
      end-binding protein 1 (EB1). The study will also measure pharmacokinetics, pharmacodynamic&#xD;
      effects and assess biomarkers.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 2015</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1: Maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of daily oral BAL101553 based on the number of participants with adverse effects as measure of tolerability at various dose levels</measure>
    <time_frame>28 day cycles</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2a: Best objective response according to RANO criteria</measure>
    <time_frame>28 day cycles</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of daily oral BAL101553 based on the number of participants with adverse events at various dose levels</measure>
    <time_frame>28 day cycles</time_frame>
    <description>Incidence of adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of daily oral BAL101553 based on the number of participants with safety laboratory changes versus baseline</measure>
    <time_frame>28 day cycles</time_frame>
    <description>Incidence of clinically relevant laboratory changes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of daily oral BAL101553 based on the number of participants with ECG changes versus baseline</measure>
    <time_frame>28 day cycles</time_frame>
    <description>Incidence of clinically relevant ECG changes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of BAL101553 and BAL27862</measure>
    <time_frame>28 day cycles</time_frame>
    <description>Pharmacokinetic parameter &quot;Peak Plasma Concentration&quot; Cmax of BAL101553 and BAL27862</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of BAL101553 and BAL27862</measure>
    <time_frame>28 day cycles</time_frame>
    <description>Pharmacokinetic parameter &quot;Time to Peak Plasma Concentration&quot; Tmax of BAL101553 and BAL27862</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC of BAL101553 and BAL27862</measure>
    <time_frame>28 day cycles</time_frame>
    <description>Pharmacokinetic parameter &quot;Area under the plasma concentration versus time curve&quot; AUC of BAL101553 and BAL27862</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life of BAL101553 and BAL27862</measure>
    <time_frame>28 day cycles</time_frame>
    <description>Pharmacokinetic parameter Half-life of BAL101553 and BAL27862</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-tumor activity of daily oral BAL101553 in cancer patients based on RECIST 1.1 -criteria (measurable disease of advanced or recurrent solid tumors).</measure>
    <time_frame>28 day cycles</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-tumor activity of daily oral BAL101553 in cancer patients by contrast-enhanced MRI based on RANO criteria (recurrent or progressive GBM or high-grade glioma).</measure>
    <time_frame>28 day cycles</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">104</enrollment>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>Drug: BAL101553</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral daily administration of BAL101553</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral daily administration of BAL101553</intervention_name>
    <description>oral administration</description>
    <arm_group_label>Drug: BAL101553</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 18 years&#xD;
&#xD;
          2. Patients who have in the&#xD;
&#xD;
             Phase 1 portion either of the following:&#xD;
&#xD;
               1. a histologically- or cytologically confirmed advanced or recurrent solid tumor,&#xD;
                  who failed standard therapy, or for whom no effective standard therapy is&#xD;
                  available to them&#xD;
&#xD;
               2. histologically-confirmed GBM or high-grade glioma, with progressive or recurrent&#xD;
                  disease after prior radiotherapy, with or without chemotherapy. This will also&#xD;
                  include patients with histologically-confirmed low-grade glioma who present with&#xD;
                  unequivocal evidence by imaging of transformation to high-grade glioma/GBM.&#xD;
&#xD;
             Phase 2 portion: Recurrent, histologically confirmed, glioblastoma with tumor tissue&#xD;
             positive for EB1; eligible are patients with de novo glioblastoma after prior radical&#xD;
             chemo-radiotherapy or secondary glioblastoma after prior chemotherapy or radiotherapy.&#xD;
&#xD;
          3. Patients must have measurable disease.&#xD;
&#xD;
          4. Life expectancy ≥ 12 weeks&#xD;
&#xD;
          5. Acceptable organ and marrow function at baseline (protocol defined laboratory&#xD;
             parameters)&#xD;
&#xD;
          6. Patients with advanced solid tumors must have an Eastern Cooperative Oncology Group&#xD;
             (ECOG) performance status ≤ 1 and patients with recurrent or progressive glioblastoma&#xD;
             must have an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.&#xD;
&#xD;
          7. Other protocol-defined inclusion criteria may apply.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with advanced or recurrent solid tumors who have received chemotherapy,&#xD;
             radiotherapy, immunotherapy, or investigational agents within 4 weeks prior to&#xD;
             starting study drug or who have not recovered from side effects of prior therapies.&#xD;
&#xD;
             Patients with recurrent or progressive GBM or high-grade glioma who have: received&#xD;
             radiotherapy within 12 weeks, unless there is a new area of enhancement consistent&#xD;
             with recurrent tumor outside the radiation field, or there is histological&#xD;
             confirmation of unequivocal tumor progression; received administration of prior&#xD;
             antitumor chemotherapy within 4 weeks, or within 6 weeks for nitrosoureas; undergone&#xD;
             surgical resection within 4 weeks or a stereotactic biopsy/core biopsy within 1 week&#xD;
             prior to starting study drug.&#xD;
&#xD;
          2. Patients who have had prior exposure to BAL1015533.&#xD;
&#xD;
          3. Inability to swallow oral medication&#xD;
&#xD;
          4. Increase in steroid dose in GBM or high-grade glioma patients within 5 days prior to&#xD;
             first study-drug administration or requirement for &gt; 6 mg/day dexamethasone or&#xD;
             equivalent for symptom control.&#xD;
&#xD;
          5. Patients with gastrointestinal disease or those who have had a procedure that is&#xD;
             expected to interfere with the oral absorption or tolerance of BAL101553&#xD;
&#xD;
          6. Symptomatic brain metastases or leptomeningeal disease, indicative of active disease,&#xD;
             in patients with advanced or recurrent solid tumors.&#xD;
&#xD;
          7. Peripheral neuropathy ≥ CTCAE grade 2.&#xD;
&#xD;
          8. Uncontrolled intercurrent illness that would unduly increase the risk of toxicity or&#xD;
             limit compliance with study requirements&#xD;
&#xD;
          9. Systolic blood pressure (SBP) ≥ 160 mmHg or diastolic blood pressure (DBP) ≥ 100 mmHg&#xD;
             at the screening visit.&#xD;
&#xD;
         10. Blood pressure (BP) combination treatment with more than two antihypertensive&#xD;
             medications.&#xD;
&#xD;
         11. Women who are pregnant or breast-feeding. Men or women of reproductive potential who&#xD;
             are not willing to apply effective birth control&#xD;
&#xD;
         12. Other protocol-defined exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Kaindl, MD</last_name>
    <role>Study Director</role>
    <affiliation>Basilea Pharmaceutica International Ltd</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Thomas Kaindl, MD</last_name>
    <phone>+41 61 567 15 24</phone>
    <email>thomas.kaindl@basilea.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stephanie Anderson</last_name>
    <phone>+41 61 567 15 24</phone>
    <email>stephanie.anderson@basilea.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Klinikum der Goethe-Universität Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <zip>60528</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joachim Steinbach, Professor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antje Wick, PD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Regensburg</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Peter Hau, Professor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Tübingen</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ghazaleh Tabatabai, Professor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsspital Basel</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heinz Läubli, Professor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Inselspital Universitätsspital Bern</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simon Häfliger, Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kantonsspital St. Gallen</name>
      <address>
        <city>St. Gallen</city>
        <zip>9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Hundsberger, PD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsspital Zürich</name>
      <address>
        <city>Zürich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick Roth, Professor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beatson West of Scotland Cancer Centre</name>
      <address>
        <city>Glasgow</city>
        <zip>G12 0YN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeff Evans, Professor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University College London NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>NW1 2BU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sir Bobby Robson Cancer Trials Research Centre; Northern Centre for Cancer Care</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruth Plummer, Professor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Marsden Hospital</name>
      <address>
        <city>Sutton</city>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juanita Lopez, MRCP</last_name>
    </contact>
    <investigator>
      <last_name>Juanita Lopez, MRCP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 25, 2015</study_first_submitted>
  <study_first_submitted_qc>July 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 7, 2015</study_first_posted>
  <last_update_submitted>June 30, 2021</last_update_submitted>
  <last_update_submitted_qc>June 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

